In the same period a year ago the company posted a loss of 70 cents a share on sales of $444.2 million.
The stock has risen 33.4% since the company last reported earnings on Oct. 30.
Quarterly estimates have fallen 3 cents a share in the past month.
Incyte is currently trading at a price-to-forward-earnings ratio of 56.1 based on the 12-month estimates of 19 analysts surveyed by FactSet.
Jim Cramer and the AAP team are watching the biotechnology sector. To find out more about what stocks they like in the industry click here now.